SLC5A2 and diabetic kidney disease: Clinically, angiotensin-converting enzyme inhibitors and (angiotensin receptor blockers) are considered effective in treating DKD.[5,6] Inflammation and renal fibrosis are difficult to prevent with these drugs.[7,8] In addition, it is clinically found that sodium-glucose cotransporter 2 inhibitor helps in controlling the progression of DM to DKD.